Behçet’s Disease: Causes, Symptoms, and Complications

Behçet’s disease is a chronic inflammatory condition that causes recurring painful ulcers in the mouth and genitals, along with eye inflammation and a tendency toward dangerous blood clots. It stands apart from most autoimmune diseases because it attacks blood vessels of every size, from tiny capillaries to major arteries and veins, which is why specialists classify it as a systemic vasculitis. The disease clusters heavily along the ancient Silk Road trade routes, from East Asia through the Middle East and into the Mediterranean, though it occurs worldwide and can affect anyone.

Who Gets Behçet’s Disease

The geographic pattern of Behçet’s disease is striking. Turkey has the highest reported rates, followed by Iran, Japan, and South Korea. Prevalence drops sharply in Northern Europe and the Americas. The disease typically appears between the ages of 20 and 40, and while both sexes are affected, men tend to develop more severe forms, especially vascular and eye complications. A familial link exists in a minority of cases, though Behçet’s is not inherited in a straightforward way.

Geography also shapes which organs the disease targets. Cardiac involvement is relatively uncommon among Caucasian patients compared to those of Asian or Middle Eastern descent, while neurological complications are more frequently reported in Caucasians.¹ This variation means that a person’s ethnic background and where they live can influence not just their likelihood of developing Behçet’s but which symptoms dominate.

The Genetic Landscape

The strongest known genetic risk factor is a gene variant called HLA-B*51. In countries where Behçet’s is common, roughly half to four-fifths of patients carry this variant, and the odds of developing the disease if you have it are about five to ten times higher than if you don’t. In non-endemic areas like North America, the association is weaker, with an odds ratio closer to 2.35.² Carrying HLA-B*51 is neither necessary nor sufficient for disease, though. Plenty of people with the variant never develop Behçet’s, and some patients lack it entirely.

Beyond HLA-B*51, large-scale genetic studies have identified more than a dozen other risk spots in the genome. These include genes involved in inflammation and immune signaling, such as IL10, IL23R, STAT4, CCR1, KLRC4, ERAP1, and TNFAIP3.³ One finding that has particularly interested researchers is an interaction between HLA-B*51 and ERAP1, a gene encoding a protein that trims other proteins into the right size to be presented on cell surfaces. When both variants are present together, risk increases in a way that suggests the immune system’s ability to recognize and present peptides to immune cells is fundamentally involved.⁴ Several of these same genetic risk factors also appear in spondyloarthritis, a group of inflammatory joint diseases, hinting that the two conditions share some underlying inflammatory pathways.⁵

What Drives the Inflammation

Behçet’s disease sits uncomfortably between autoimmune and autoinflammatory conditions. The immune system’s adaptive arm (T cells responding to specific targets) and its innate arm (first-responder cells that attack broadly) both contribute. For years, researchers focused on a type of immune cell called Th1 cells, which are elevated in patients and produce inflammatory signaling molecules like interferon-gamma and TNF-alpha.⁶ More recently, a second population called Th17 cells, which drive inflammation through the IL-17/IL-23 pathway, has been implicated as well. Studies of intestinal tissue from Behçet’s patients have found both Th1 and Th17 cells infiltrating the gut lining, with some hybrid cells producing both interferon-gamma and IL-17.⁷

Neutrophils, the most abundant white blood cells, also play a central role. In active disease, neutrophils are primed to release web-like structures made of their own DNA, called neutrophil extracellular traps. These traps are normally deployed to catch bacteria, but in Behçet’s patients they appear spontaneously and in excess. When researchers examined biopsies from inflamed blood vessels, they found these DNA webs clustered around sites of vasculitis and clot formation.⁸ The traps boost clot formation by increasing thrombin generation, and when scientists broke down the DNA in blood samples with an enzyme, clotting activity dropped significantly in Behçet’s plasma but not in healthy controls. Lab work has also shown that these traps damage the cells lining blood vessels, reducing their ability to divide and increasing cell death.⁹ This helps explain why the disease has such a strong tendency toward both blood vessel inflammation and clotting.

The gut microbiome may be another piece of the puzzle. Behçet’s patients show altered communities of oral and gut bacteria, and some of those bacteria contain proteins structurally similar to human proteins. This molecular mimicry could trick the immune system into attacking the body’s own tissues.¹⁰

The Hallmark Symptoms

Mouth ulcers are almost universal in Behçet’s disease and are typically the earliest sign.¹¹ They look similar to ordinary canker sores but tend to be larger, more frequent, and often come in clusters. The difference from garden-variety aphthous ulcers is that Behçet’s ulcers recur relentlessly, sometimes barely healing before a new round begins. Because mouth ulcers are so common in the general population, many people cycle through years of misdiagnosis before additional symptoms appear.

Genital ulcers are the second hallmark. In men, they usually appear on the scrotum; in women, on the vulva. These ulcers tend to be deeper and more painful than oral ones, and they can leave scars, which oral ulcers typically do not. Skin problems are also common and range from acne-like nodules to a raised, tender rash on the shins called erythema nodosum. These mucocutaneous findings are so central that the diagnostic criteria for Behçet’s disease are built around them.¹²

Eye Involvement

Uveitis, or inflammation inside the eye, occurs in roughly 40% of people with Behçet’s disease and is the complication that frightens most patients. The most common pattern is panuveitis, meaning inflammation affects both the front and back of the eye. Men are more frequently and more severely affected. The estimated risk of blindness over five years sits around 10 to 15%.¹³ Early and aggressive treatment has improved these numbers over the past couple of decades, but uveitis still remains a leading cause of acquired visual impairment in young adults in endemic countries. Flares can strike without warning, and each episode carries the risk of cumulative retinal damage.

Vascular Complications

Behçet’s disease is unusual among vasculitides because it targets both veins and arteries. Vascular involvement shows up in roughly 7 to 29% of patients, depending on the population studied.¹⁴ Deep vein thrombosis of the legs is the most common vascular event, but clots can also form in more dangerous locations. Thrombosis of the large central veins, including the inferior vena cava, and Budd-Chiari syndrome (blockage of the liver’s drainage veins) are recognized complications that demand intensive immunosuppressive treatment.¹⁵ On the arterial side, aneurysms, particularly of the pulmonary arteries, can be life-threatening and often require surgical or endovascular repair alongside immunosuppression.¹⁶

One important clinical distinction is that Behçet’s-related clots are driven by vessel wall inflammation rather than the typical coagulation abnormalities seen in conditions like antiphospholipid syndrome. Standard anticoagulation alone does not address the underlying problem, which is why immunosuppression is the cornerstone of treatment for vascular Behçet’s.

Neurological and Gastrointestinal Disease

When Behçet’s disease enters the nervous system, it tends to target the brainstem, the deep white matter of the brain, and the basal ganglia. An MRI study of patients with neurological involvement found that brainstem lesions were the most common, followed closely by cerebral white matter and basal ganglia changes, with some patients also showing spinal cord involvement.¹⁷ Symptoms vary depending on where the inflammation strikes and can include headaches, confusion, difficulty with balance and coordination, and personality changes. A separate pattern involves clots in the brain’s venous sinuses, which causes severe headaches and can mimic a stroke.

Gastrointestinal Behçet’s presents its own challenge because it can look almost identical to Crohn’s disease on endoscopy. Both conditions cause deep ulcers in the gut, and when a patient lacks the typical mouth and genital ulcers that would tip off a clinician, the distinction requires careful tissue analysis.¹⁸ Getting the diagnosis right matters because the treatment strategies differ, and some drugs effective for Crohn’s are not necessarily the best choice for intestinal Behçet’s.

How Behçet’s Is Diagnosed

There is no single blood test or imaging finding that confirms Behçet’s disease. Diagnosis relies on recognizing a pattern of clinical features. The International Criteria for Behçet’s Disease use a point-based system: oral ulcers, genital ulcers, and ocular lesions each earn two points, while skin lesions, central nervous system involvement, vascular manifestations, and a positive pathergy test each earn one point. A score of four or more classifies a patient as having Behçet’s.¹⁹ The pathergy test itself is a simple skin-prick procedure. In some Behçet’s patients, a needle prick to the forearm produces an exaggerated red bump within 48 hours, reflecting the abnormal neutrophil hyperreactivity at the heart of the disease. The test is more often positive in Middle Eastern and East Asian patients than in those from Western countries.

A major diagnostic hurdle is timing. Not all features appear at once, and it can take years before enough symptoms accumulate to meet criteria. A young person with nothing but recurrent mouth ulcers might have early Behçet’s, or they might just have common aphthous stomatitis. The distinction often only becomes clear once additional manifestations develop, which means some patients endure a frustrating diagnostic limbo for years.

Treatment Approaches

Treatment is tailored to which organs are involved and how severely. For mucocutaneous symptoms like oral and genital ulcers, colchicine is often the first-line medication. Randomized trials have also shown benefits from azathioprine, interferon-alpha, thalidomide, and apremilast for skin and mucous membrane disease, though the response varies by lesion type and sex.²⁰ Apremilast, which works by blocking a specific enzyme involved in inflammation, has shown particular promise for oral ulcers.²¹

For more serious organ involvement, anti-TNF biologic drugs like infliximab and adalimumab have transformed outcomes. A multicenter study of 124 patients with severe or treatment-resistant disease found an overall response rate above 90%. The rate of disease flares dropped dramatically during anti-TNF treatment, and steroid doses were significantly reduced within a year. Side effects were reported in about 28% of patients, mainly infections, and serious adverse events occurred in about 13%.²² For patients who don’t respond to anti-TNF drugs, newer biologics targeting IL-1, IL-6, or IL-12/IL-23 are being used. Tocilizumab, which blocks IL-6, has shown efficacy in eye disease, while anakinra and ustekinumab appear promising for mucocutaneous symptoms that resist other therapies.²³

Pregnancy and Behçet’s Disease

For women with Behçet’s, pregnancy is generally not made more dangerous by the disease itself. Most women find that their symptoms actually improve during pregnancy, though the pattern is unpredictable from one pregnancy to the next.²⁴ Corticosteroids, azathioprine, calcineurin inhibitors, and probably colchicine are considered safe during pregnancy and breastfeeding. The drugs that must be avoided include methotrexate, mycophenolate mofetil, thalidomide, and cyclophosphamide due to their potential to cause birth defects.

The main pregnancy-specific concern is vasculopathy. Because Behçet’s inflames blood vessels, women with vascular involvement may face a higher risk of pregnancy complications, and anticoagulant therapy should be considered.²⁵ Close monitoring by both a rheumatologist and an obstetrician throughout pregnancy is the standard approach.

Prognosis and Mortality

Behçet’s disease is rarely fatal, but it is not benign. In a large cohort of 817 patients followed for a median of nearly eight years, about 5% died, and the overwhelming majority of those deaths were in men. The leading cause of death was major vessel disease, including arterial aneurysms and Budd-Chiari syndrome, accounting for over 40% of fatalities. Cancer, neurological involvement, and sepsis made up most of the remainder. Young men between 15 and 34 years old had roughly three times the expected mortality of the general population. Male sex, arterial involvement, and frequent disease flares were independently linked to higher risk of death.²⁶

Beyond mortality, the disease’s impact on daily life is substantial. Fatigue is one of the most disabling but least visible symptoms, and studies have found that both the physical and mental health dimensions of quality of life are significantly impaired. Depression and anxiety are common, and patients with active disease report worse fatigue, more disability, and lower quality of life across the board.²⁷ The unpredictable, relapsing nature of the disease makes it difficult for patients to plan their lives around it. Flares can derail work, travel, and relationships without warning.

Behçet’s Disease in Children

Behçet’s can begin in childhood, though it is less common and tends to look somewhat different than adult-onset disease. Familial cases, where a close relative also has Behçet’s, are more frequent in children than adults. Joint involvement tends to be more prominent in the pediatric population, whereas venous clots are more common in adults.²⁸ Neurological and gastrointestinal manifestations have also been reported at higher rates in juvenile-onset disease.²⁹

Diagnosing Behçet’s in children poses its own challenges. Oral ulcers, the most common first symptom in both adults and children, are extremely common in childhood for many other reasons. Genital ulcers, which help clinch the diagnosis in adults, appear less frequently in children at disease onset. Pediatric patients are also more likely to be treated with steroids alone or even to receive no specific therapy initially, while adults more often require conventional or biologic immunosuppressive drugs. Whether these prescribing differences reflect genuinely milder childhood disease or simply diagnostic uncertainty remains an open question. Researchers are now exploring whether digital symptom tracking combined with machine learning could help detect disease flares earlier in pediatric patients, though this work is still in early proof-of-concept stages.³⁰

1
PubMed Central. Behcet’s Disease: Is There Geographical Variation? A Review Far from the Silk Road ↩︎
2
PubMed Central. The association of Behçet’s syndrome with HLA-B51 as understood in 2021 ↩︎
3
PubMed Central. The immunogenetics of Behçet’s disease: A comprehensive review ↩︎
4
PubMed. Pathogenesis of Behçet’s disease: autoinflammatory features and beyond ↩︎
5
Current Opinion in Rheumatology. Genetics of Behçet’s disease: lessons learned from genomewide association studies ↩︎
6
PubMed Central. The Role of Th17 Cells in the Pathogenesis of Behcet’s Disease ↩︎
7
PubMed Central. Cytotoxic Th1 and Th17 cells infiltrate the intestinal mucosa of Behcet patients and exhibit high levels of TNF-α in early phases of the disease ↩︎
8
Annals of the Rheumatic Diseases. Critical role of neutrophil extracellular traps (NETs) in patients with Behcet’s disease ↩︎
9
PubMed. Neutrophils contribute to vasculitis by increased release of neutrophil extracellular traps in Behçet’s disease ↩︎
10
PubMed. The role of bacteria and viruses in Behçet syndrome: Should we move towards new paradigms? ↩︎
11
PubMed Central. Behçet’s disease, painful genital ulcerations and steroid pulse therapy ↩︎
12
PubMed. Behçet Disease: An Update for Dermatologists ↩︎
13
PubMed Central. Behçet’s Disease Uveitis ↩︎
14
The Open Cardiovascular Medicine Journal. Behçet’s Disease as a Model of Venous Thrombosis ↩︎
15
PubMed Central. Cardiovascular Manifestations in Behçet’s Disease ↩︎
16
PubMed Central. Behçet’s Syndrome and Thrombosis ↩︎
17
PubMed Central. Radiological findings in Behçet disease ↩︎
18
PubMed Central. Intestinal Behçet’s disease presenting with intestinal obstruction misdiagnosed as Crohn’s disease: a case report ↩︎
19
PubMed. The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria ↩︎
20
PubMed. Management of skin, mucosa and joint involvement of Behçet’s syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet’s syndrome ↩︎
21
Archives of Rheumatology. New and future perspectives in Behçet’s syndrome ↩︎
22
PubMed. Efficacy of anti-TNF alpha in severe and/or refractory Behçet’s disease: Multicenter study of 124 patients ↩︎
23
PubMed Central. Biologic treatments in Behçet’s disease ↩︎
24
PubMed Central. Behçet’s syndrome in pregnancy ↩︎
25
PubMed Central. Behçet’s disease in pregnancy: a case report and literature review ↩︎
26
PubMed. Mortality in Behçet’s disease ↩︎
27
PubMed. Fatigue in patients with Behçet’s syndrome: relationship with quality of life, depression, anxiety, disability and disease activity ↩︎
28
PubMed. Behçet syndrome in children and adults: discovering similarities and differences by a comparative study ↩︎
29
PubMed. Demographic and clinical properties of juvenile-onset Behçet’s disease: A controlled multicenter study ↩︎
30
SpringerLink. Tree-based machine learning models recover rule-based flare labels from virtual symptom diaries in pediatric Behçet’s disease: an in silico proof-of-concept study ↩︎